NAV

Amniotic Epithelial Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Amniotic Epithelial Cells
Accession Number
DB15868
Description

Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus.1,2 These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.1

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • hAECs
  • Human Amniotic Epithelial Cells
External IDs
  • Amniotic Epithelial Cells

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Amniotic epithelial cells have immunosuppression properties, the likely reason why these cells seem to be resistant to rejection after allotransplantation. Further therapeutic effects of these cells include reported neuroprotection and neuroregeneration properties, attributed to the growth factor secretion by AECs. These cells are being investigated as a therapy against many different conditions, some of which include lung fibrosis, liver fibrosis, multiple sclerosis, congenital metabolic disorders, familial hypercholesterolemia, spinal cord injuries, ophthalmic diseases, and Parkinson’s disease.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Yang PJ, Yuan WX, Liu J, Li JY, Tan B, Qiu C, Zhu XL, Qiu C, Lai DM, Guo LH, Yu LY: Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol Sin. 2018 Aug;39(8):1305-1316. doi: 10.1038/aps.2018.22. Epub 2018 Mar 22. [PubMed:29565036]
  2. Atala A., Lanza R., Mikos T., and Nerem R. (2019). Principles of Regenerative Medicine (3rd ed.). Elsevier. [ISBN:9780128098936]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentAsherman's Syndrome1
1RecruitingTreatmentInfertility / Premature Ovarian Failure (POF) / Primary Ovarian Insufficiency1
1Unknown StatusTreatmentHTLV-1 Associated Myelopathy1
1Unknown StatusTreatmentSpastic Cerebral Palsy1
1, 2Not Yet RecruitingTreatmentNonunion Fractures1
Not AvailableRecruitingPreventionAcute-graft-versus-host Disease / Graft Versus Host Disease, Acute1
Not AvailableUnknown StatusTreatmentPremature Ovarian Failure (POF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 21, 2020 15:44 / Updated on September 22, 2020 13:00